Ton Slagboom

Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent – five-year results of the TARGET All Comers randomised clinical trial

Lansky AJ, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson TW, Vlachojannis GJ, Arkenbout KE, Holmvang L, Janssens L, Brugaletta S, Naber CK, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina CM, Buszman PE, Thiele H, Schächinger V, Wijns W

December 4, 2023 | 10.4244/EIJ-D-23-00409

Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial

Slagboom T, Toelg R, Witzenbichler B, Haude M, Masotti M, Ruiz Salmeron R, Witkowski A, Uematus M, Takahashi A, Waksman R, Saito S

February 20, 2023 | 10.4244/EIJ-D-22-00526

BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months

Saito S, Toelg R, Witzenbichler B, Haude M, Masotti M, Ruiz Salmeron R, Witkowski A, Uematsu M, Takahashi A, Waksman R, Slagboom T

December 6, 2019 | 10.4244/EIJ-D-18-01214

Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers

Baumbach A, Lansky AJ, Onuma Y, Asano T, Johnson TW, Anderson R, Kiemeneij F, Zeng M, van Royen N, Slagboom T, Vlachojannis GJ, Serruys P, Wijns W

November 20, 2018 | 10.4244/EIJ-D-18-00226

Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials

Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Kandzar D, Donohoe D, Ormiston J

April 6, 2018 | 10.4244/EIJ-D-17-00230

Direct implantation of rapamycin-eluting stents with bioresorbable drug carrier technology utilising the Svelte coronary stent-on-a-wire: the DIRECT II study

Verheye S, Khattab A, Carrié D, Stella P, Slagboom T, Bartunek J, Onuma Y, Serruys P

August 5, 2016 | 10.4244/EIJV12I5A101

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial

Vlachojannis GJ, Smits PC, Hofma S, Togni M, Vázquez N, Valdes M, Voudris V, Puricel S, Slagboom T, Goy J-J, den Heijer P, van der Ent M

July 20, 2015 | 10.4244/EIJV11I3A53

Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial

Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani G, Lansky AJ, Ormiston J

April 20, 2015 | 10.4244/EIJY14M05_03

Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study

Vos N, Dirksen M, Vink M, van Nooijen F, Amoroso G, Herrman JP, Kiemeneij F, Patterson M, Slagboom T, van der Schaaf R

September 28, 2014 | 10.4244/EIJV10I5A101

Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry

Toelg R, Merkely B, Erglis A, Hoffmann S, Bruno H, Kornowski R, Slagboom T, Naber CK, Witzenbichler B, Graf K, Richardt G, Hehrlein C

September 28, 2014 | 10.4244/EIJV10I5A102

Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II)

Teeuwen K, Van den Branden B, Rahel B, Laarman G, Thijssen J, Kelder J, Slagboom T, ten Berg JM, Suttorp MJ

June 28, 2013 | 10.4244/EIJV9I2A36

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)

Van den Branden B, Rahel B, Laarman G, Slagboom T, Kelder J, ten Berg JM, Suttorp MJ

February 21, 2012 | 10.4244/EIJV7I10A190

Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial

Silber S, Gutiérrez-Chico J-L, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Naber CK, Chevalier B, Serruys P

May 17, 2011 | 10.4244/EIJV7I1A13

Magnetically navigated percutaneous coronary intervention in distal and/or complex lesions may improve procedural outcome and material consumption

IJsselmuiden AJ, Patterson M, van Nooijen F, Tangelder G-J, Dirksen M, Amoroso G, Slagboom T, Serruys P, Laarman GJ, Kiemeneij F

January 20, 2009

Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study

Dirksen M, Vink M, Suttorp MJ, Thijssen J, Patterson M, Slagboom T, Kiemeneij F, Laarman GJ

May 13, 2008

Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD

Serruys P, Vranckx P, Slagboom T, Regar E, Meliga E, de Winter R, Heyndrickx G, Schuler G, van Remortel E, Dubé GP, Symons J

March 20, 2008

Ton Slagboom

Latest news